Abstracts tagged "rheumatoid arthritis (RA) and infection"

Abstract Number: 1800 • 2019 ACR/ARP Annual Meeting
Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis)
Ori Elkayam¹, Itzhak Rosner ², Devy Zisman ³, Merav Lidar ⁴, Reuven Mader ⁵, Amir Bieber ⁵, Alexandra Balbir-Gurman ⁶, Mirit Amit ⁷, Smadar Gertel ⁸ and Victoria Furer ⁹, ¹Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel, ²Bnei Tzion, Haifa, Israel, ³Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Ha emek medical center, Afula, Israel, ⁶Rambam Medical Center, Haifa, Israel, ⁷Shamir medical center, Zerifin, Israel, ⁸Tel Aviv medical center, Tel Aviv, Israel, ⁹Sourasky Medical Center, Tel-Aviv, Israel
Background/Purpose: To evaluate the safety and humoral immunogenicity of a live attenuated herpes zoster (HZ) vaccine in patients with rheumatoid arthritis (RA) compared with healthy…
Abstract Number: 2116 • 2019 ACR/ARP Annual Meeting
Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data
Lisa Lindsay¹, Ching-Yi Chuo ², Nicholas Jones ², Joshua Galanter ², Anna McGregor ² and Katie Tuckwell ², ¹Genentech Inc, SOUTH SAN FRANCISCO, CA, ²Genentech Inc, SOUTH SAN FRANCISCO
Background/Purpose: Patients with systemic lupus erythematosus (SLE), lupus nephritis (LN) and rheumatoid arthritis (RA) are at risk of serious infections (SIs) due to the impact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].